4,901 trials
Renal Impairment · Tuberculosis
Primary: Fold Change in Pretomanid AUC(0-last) in Participants With Renal Impairment as Compared to Matched Healthy Controls — 77130; 63600; 62660 ng*h/mL
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) up to 24 Months — 0; 0; 0; 0 Participants
Alzheimer's Disease
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 3; 5; 2; 6 Participants
Cardiotoxicity · Risk Factor, Cardiovascular · Toxicity Due to Chemotherapy
Primary: Left Ventricular Ejection Fraction (LVEF) — 61.1; 59.0; 61.9; 58.4 percent
Neoplasms
Primary: Maximum Tolerated Dose (MTD) of BI 836880 Monotherapy and Combination Therapy of BI 836880 and BI754091 — NA; NA milligram
Healthy Volunteer
Primary: Maximum Observed Serum Concentration (Cmax) of Tocilizumab — 10.5; 10.0 micrograms per milliter (μg/mL)
Glioblastoma · Brain Tumor · GBM
Primary: Maximum Tolerated Dose (MTD) — 100; 300 mg/day Vorinostat
Healthy
Primary: Decrease in Cinnamaldehyde (CA)-Induced Dermal Blood Flow (DBF) Relative to Placebo Measured by Laser Doppler Imaging (LDI) at 3 Hours Post-dose (LDI) — -9.46; -6.96…
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 180 Milligram (mg)
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 720 Milligram
Safety · Pharmacokinetics · Pharmacodynamics
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 1; 1; 5; 4 Participants
Heart Failure · Type 2 Diabetes Mellitus
Primary: Cardiac Output (CO) — 5.02; 4.54; 5.93; 5.10 mL/min
Healthy
Primary: The Mean (SD) Amount of [14C] Recovered in Urine, as a Percent of the Total [14C] Dose Administered — 25.2 percentage of dose
Nosocomial Pneumonia
Primary: Percentage of Participants With Any Adverse Events (AEs) — 50.0; 71.4; 75.0; 90.0 Percentage of participants
Healthy
Primary: Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 3014; 4255 Nanomoles * hour per Liter